Puma Biotechnology (PBYI) Liabilities and Shareholders Equity (2010 - 2026)

Puma Biotechnology has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $192.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 1.77% year-over-year to $192.7 million; the trailing twelve-month figure through Mar 2026 stood at $806.8 million (down 3.41% YoY), and the FY2025 full-year result was $216.3 million, up 1.39% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $192.7 million, down from $216.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $230.5 million in Q4 2023, with the low at $192.7 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $206.0 million across 5 years, with a median of $202.9 million in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity fell 25.52% — and 2024, when it gained 9.12%.
• Puma Biotechnology's Liabilities and Shareholders Equity stood at $222.1 million in 2022, then advanced by 3.81% to $230.5 million in 2023, then slipped by 7.46% to $213.3 million in 2024, then gained by 1.39% to $216.3 million in 2025, then decreased by 10.91% to $192.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $192.7 million (Q1 2026), $216.3 million (Q4 2025), and $202.9 million (Q3 2025), per Business Quant data.